OncoDaily Announces Strategic Partnership with the Asian Fund for Cancer Research Limited (AFCR)

OncoDaily is pleased to announce a strategic partnership with the Asian Fund for Cancer Research Limited (AFCR). This collaboration is designed to enhance the dissemination of cancer research-related information across Asia, create impactful educational content, organize joint events, and more. Together, we aim to promote awareness, recognize excellence, and improve access to high-quality cancer research throughout the region.

This partnership represents a significant step forward in our shared mission to advance cancer research and make a meaningful impact on the lives of those affected by cancer across Asia.

About OncoDaily

OncoDaily is a leading digital platform dedicated to delivering the latest news, research updates, and insights in the field of oncology. Our mission is to empower healthcare professionals, researchers, and patients by providing accessible, high-quality information that fosters awareness and knowledge in cancer research and treatment. With a global audience, OncoDaily is committed to being at the forefront of the fight against cancer, offering a wide range of educational content, podcasts, and expert-led discussions to inspire the oncology community.

About the Asian Fund for Cancer Research Limited (AFCR)

The Asian Fund for Cancer Research Limited (AFCR) is a tax-exempt legal charity registered with the Hong Kong Inland Revenue Department. The AFCR is committed to funding cancer research, especially those cancers prevalent in Asian populations, and promotes global collaborations for high impact to save the lives of cancer patients. In addition, AFCR provides the public with a wide variety of in-depth, user-friendly cancer prevention information and healthy lifestyle suggestions. We help the community understand the latest scientific achievements and their potential significance in improving the prevention, diagnosis, and treatment of cancer. Armed with this knowledge, people can better protect themselves against cancer.